查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2021653

即时诊断设备市场预测至2034年－按产品类型、检体类型、技术、应用、最终用户和地区分類的全球分析

Point-of-Care Diagnostic Devices Market Forecasts to 2034 - Global Analysis By Product Type, Sample Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球即时诊断设备市场规模将达到 480 亿美元，并在预测期内以 7.5% 的复合年增长率增长，到 2034 年将达到 850 亿美元。

即时诊断设备是携带式医疗设备，用于在患者就诊地点或附近进行诊断测试。这些设备能够快速检测感染疾病、血糖值和心臟标记等疾病，从而支持即时的临床决策。它们还能减少对中心检查室检测的需求，并提高医疗服务的效率。即时诊断设备广泛应用于医院、诊所和家庭环境中，支援早期诊断、及时治疗和改善患者预后，尤其是在急诊和远端医疗环境中。

慢性病增多

随着糖尿病、心血管疾病和感染疾病的日益流行，对快速、准确且便捷的诊断解决方案的需求激增。即时检测设备能够实现即时检测和结果回馈，从而支持及时的临床决策并减少患者就诊次数。其便携性和易用性使其不仅适用于临床环境，也适用于家庭环境。医疗专业人员正越来越多地采用这些设备来改善患者预后并减轻中心检查室的负担。鑑于慢性病在全球范围内日益加重，对即时诊断的需求预计将持续强劲。

监理核准的挑战

对临床检验、安全性和准确性的严格要求常常导致产品上市延迟。製造商面临着复杂且因地区而异的核准流程，这增加了成本并减缓了全球推广。中小企业尤其难以克服这些监管障碍，限制了创新。医疗机构在获得全面监管批准之前可能犹豫是否要引入新设备，这进一步延缓了产品的普及。儘管监管机构旨在确保病患安全，但漫长的核准週期却阻碍了产品的快速商业化。

与数位健康平台集成

将医疗设备与行动应用、电子健康记录和远端医疗平台集成，可改善数据存取和病患监测。医生可以远端追踪患者的检测结果，从而实现预防性介入和个人化治疗方案。检测结果可以即时共用给医疗服务提供者，使患者受益，并提高就医便利性和参与度。这种整合还支援大规模社区健康管理和慢性病监测。为了顺应数位化医疗的发展趋势，各公司正在增加对互联诊断技术的投资。随着医疗系统采用数位化优先模式，这些整合机会有望推动显着成长。

低成本设备带来的价格压力

新兴经济体的许多本土製造商正在提供价格亲民的即时检测（PoC）解决方案，这对老牌大型企业构成了挑战。在价格敏感的市场中，成本往往优先于先进功能，从而限制了高级产品的利润空间。这种竞争环境迫使企业在创新与价格可负担之间寻求平衡。医疗服务提供者可能会选择更便宜的替代方案，即使这些方案缺乏先进的连接性或分析能力。商品化的威胁在血糖值监测和快速感染疾病检测等领域尤为突出。

新冠疫情的影响：

新冠疫情显着加速了即时诊断设备的应用。快速检测对于控制疫情传播至关重要，由此产生了对携带式诊断解决方案前所未有的需求。疫情期间，各国政府和医疗系统对即时检测基础设施进行了大量投资。疫情也凸显了分散式诊断的重要性，有助于减少对集中式检查室的依赖。疫情过后，随着医疗服务提供者认识到快速诊断在慢性病管理和急诊医学的价值，这一趋势仍在持续。製造商正利用从新冠疫情中汲取的经验教训，拓展产品系列併加强供应链。

在预测期内，免疫检测领域预计将占据最大的市场份额。

随着慢性病盛行率的不断上升，对快速、准确的生物标记检测的需求日益增长，预计在预测期内，免疫检测领域将占据最大的市场份额。免疫检测广泛应用于感染疾病诊断、慢性病监测和癌症标记检测。由于其多功能性和可靠性，免疫检测是即时诊断的基础。微流体技术和携带式平台的进步正在提高免疫检测的效率。医院、诊所和居家医疗机构越来越依赖这些检测来进行快速决策。已开发市场和新兴市场对该领域的强劲需求都支撑着这一细分市场的发展。

在预测期内，居家照护环境细分市场预计将呈现最高的复合年增长率。

在预测期内，受慢性病患病率上升以及由此产生的对便捷家庭诊断解决方案的需求推动，居家照护环境领域预计将呈现最高的增长率。糖尿病、心血管疾病和呼吸系统疾病患者越来越依赖即时检测设备进行自我管理。家庭诊断可以减少就医次数，提高治疗顺从性，并帮助患者更好地掌控自身健康。这一领域受益于可与行动应用程式和远端医疗平台整合的连网型设备的日益普及。不断上涨的医疗保健成本和人口老化进一步推动了居家照护的转型。製造商正致力于开发用户友好、便于携带且针对家庭使用进行最佳化的设备。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的医疗保健基础设施以及慢性病在总人口中日益普遍的患病率。美国在即时诊断技术的核准方面处于主导地位，这得益于其健全的报销体系和监管审批。市场主要企业总部均设在该地区，推动创新和商业化进程。糖尿病、心血管疾病和癌症的高发生率推动了对快速诊断的需求。该地区还受益于数位健康平台和即时诊断设备的深度整合。对研发和临床试验的持续投入进一步巩固了其市场领导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗保健的快速数位化以及新兴经济体慢性病盛行率的上升。中国、印度和东南亚等国家对价格合理且易于取得的诊断服务的需求日益增长。各国政府正在加大对医疗基础设施的投资，并推广分散式检查以增强医疗公平性。本土製造商提供高性价比的解决方案，促进了价格敏感型市场的普及。智慧型手机普及率的提高和远端医疗措施正在推动即时检测设备与数位平台的整合。预防医学意识的增强也进一步推动了市场扩张。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球即时诊断设备市场：依产品类型划分

  • 血糖监测设备
  • 传染病检查设备
  • 心臟标记检测装置
  • 血液气体和电解质分析仪
  • 其他产品类型

第六章 全球即时诊断设备市场：依样本类型划分

  • 血
  • 尿
  • 唾液
  • 鼻咽拭子
  • 其他检体类型

第七章 全球即时诊断设备市场：依技术划分

  • 横向流动化验
  • 免疫检测
  • 分子诊断
  • 微流体技术
  • 生物感测器
  • 其他技术

第八章 全球即时诊断设备市场：按应用划分

  • 糖尿病检测
  • 心血管疾病
  • 肿瘤检查
  • 妊娠和不孕症检查
  • 其他用途

第九章 全球即时诊断设备市场：依最终用户划分

  • 医院
  • 诊所
  • 诊断中心
  • 居家医疗环境
  • 其他最终用户

第十章 全球即时诊断设备市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Danaher Corporation
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • QuidelOrtho Corporation
  • PerkinElmer Inc.
  • Sekisui Diagnostics
  • Trinity Biotech
  • Arkray Inc.
  • SD Biosensor Inc.
  • Werfen
  • Hologic Inc.
  • Fujifilm Holdings Corporation
Product Code: SMRC35102

According to Stratistics MRC, the Global Point-of-Care Diagnostic Devices Market is accounted for $48 billion in 2026 and is expected to reach $85 billion by 2034 growing at a CAGR of 7.5% during the forecast period. Point-of-Care Diagnostic Devices are portable medical tools used to perform diagnostic tests at or near the site of patient care. These devices provide rapid results for conditions such as infections, blood glucose levels, cardiac markers, and more, enabling immediate clinical decisions. They reduce the need for centralized laboratory testing and improve efficiency in healthcare delivery. Widely used in hospitals, clinics, and home settings, point-of-care devices support early diagnosis, timely treatment, and improved patient outcomes, particularly in emergency and remote care environments.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

Rising cases of diabetes, cardiovascular disorders, and infectious diseases have created urgent demand for rapid, accurate, and accessible diagnostic solutions. Point-of-care devices enable immediate testing and results, supporting timely clinical decisions and reducing hospital visits. Their portability and ease of use make them suitable for both clinical and home settings. Healthcare providers are increasingly adopting these devices to improve patient outcomes and reduce the burden on centralized laboratories. The growing global burden of chronic illnesses is expected to sustain strong demand for point-of-care diagnostics.

Restraint:

Regulatory approval challenges

Stringent requirements for clinical validation, safety, and accuracy often delay product launches. Manufacturers face complex approval processes across different regions, which increases costs and slow global expansion. Smaller companies, in particular, struggle to navigate these regulatory hurdles, limiting innovation. Healthcare providers may hesitate to adopt new devices until they receive full regulatory clearance, further slowing uptake. While regulatory bodies aim to ensure patient safety, the lengthy approval timelines remain a barrier to rapid commercialization.

Opportunity:

Integration with digital health platforms

Linking devices with mobile apps, electronic health records, and telehealth platforms enhances data accessibility and patient monitoring. Physicians can remotely track patient results, enabling proactive interventions and personalized treatment plans. Patients benefit from improved convenience and engagement, as results can be shared instantly with healthcare providers. This integration also supports population health management and chronic disease monitoring at scale. Companies are increasingly investing in connected diagnostics to align with digital health trends. As healthcare systems embrace digital-first models, integration opportunities are expected to drive significant growth.

Threat:

Pricing pressure from low-cost devices

Many local manufacturers in emerging economies offer affordable point-of-care solutions, challenging established players. Price-sensitive markets often prioritize cost over advanced features, limiting margins for premium products. This competitive environment forces companies to balance innovation with affordability. Healthcare providers may opt for cheaper alternatives, even if they lack advanced connectivity or analytics. The threat of commoditization is particularly strong in segments such as glucose monitoring and rapid infectious disease tests.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of point-of-care diagnostic devices. Rapid testing became essential for managing infection spread, driving unprecedented demand for portable diagnostic solutions. Governments and healthcare systems invested heavily in point-of-care testing infrastructure during the crisis. The pandemic also highlighted the importance of decentralized diagnostics, reducing reliance on centralized laboratories. Post-pandemic, the momentum continues as healthcare providers recognize the value of rapid diagnostics for chronic disease management and emergency care. Manufacturers are leveraging lessons from COVID-19 to expand product portfolios and strengthen supply chains.

The immunoassays segment is expected to be the largest during the forecast period

The immunoassays segment is expected to account for the largest market share during the forecast period as the increasing prevalence of chronic diseases has heightened demand for rapid and accurate biomarker detection. Immunoassays are widely used for diagnosing infectious diseases, monitoring chronic conditions, and detecting cancer markers. Their versatility and reliability make them a cornerstone of point-of-care diagnostics. Advances in microfluidics and portable platforms are enhancing the efficiency of immunoassays. Hospitals, clinics, and home care settings increasingly rely on these tests for immediate decision-making. The segment benefits from strong demand across both developed and emerging markets.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate due to the increasing prevalence of chronic diseases, which has driven demand for convenient, at-home diagnostic solutions. Patients with diabetes, cardiovascular disorders, and respiratory conditions increasingly rely on point-of-care devices for self-monitoring. Home-based diagnostics reduce hospital visits, improve adherence, and empower patients to manage their health. The segment benefits from growing adoption of connected devices that integrate with mobile apps and telehealth platforms. Rising healthcare costs and aging populations further support the shift toward home care. Manufacturers are focusing on user-friendly, portable devices tailored for home use.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and the increasing prevalence of chronic diseases across the population. The U.S. leads in adoption of point-of-care diagnostics, supported by strong reimbursement frameworks and regulatory approvals. Major players in the market are headquartered in the region, driving innovation and commercialization. High incidence of diabetes, cardiovascular disorders, and cancer fuels demand for rapid diagnostics. The region also benefits from strong integration of digital health platforms with point-of-care devices. Ongoing investments in R&D and clinical trials further strengthen market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare digitization and the increasing prevalence of chronic diseases in emerging economies. Countries such as China, India, and Southeast Asia are witnessing rising demand for affordable and accessible diagnostics. Governments are investing in healthcare infrastructure and promoting decentralized testing to improve equity. Local manufacturers are offering cost-effective solutions, boosting adoption in price-sensitive markets. Growing smartphone penetration and telehealth initiatives enhance integration of point-of-care devices with digital platforms. Rising awareness of preventive healthcare further supports market expansion.

Key players in the market

Some of the key players in Point-of-Care Diagnostic Devices Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, QuidelOrtho Corporation, PerkinElmer Inc., Sekisui Diagnostics, Trinity Biotech, Arkray Inc., SD Biosensor Inc., Werfen, Hologic Inc. and Fujifilm Holdings Corporation.

Key Developments:

In March 2026, Arkray launched a portable HbA1c analyzer for diabetes management in outpatient clinics. The device provides immediate results, enabling clinicians to adjust treatment plans during patient visits. Arkray's innovation reinforces its focus on chronic disease management through point-of-care solutions.

In September 2025, Bio-Rad introduced a compact immunoassay analyzer for decentralized oncology testing. The system supports biomarker-guided therapy decisions, offering clinicians rapid results outside central labs. Bio-Rad's innovation reflects its focus on precision diagnostics and expanding access to personalized medicine tools.

In June 2025, Sekisui Diagnostics launched a rapid point-of-care test for C-reactive protein (CRP), supporting infection and inflammation management. The device offers results in under five minutes, aiding primary care decision-making. Sekisui's expansion into portable immunoassays strengthens its role in frontline diagnostics.

Product Types Covered:

  • Glucose Monitoring Devices
  • Infectious Disease Testing Devices
  • Cardiac Marker Testing Devices
  • Blood Gas & Electrolyte Analyzers
  • Other Product Types

Sample Types Covered:

  • Blood
  • Urine
  • Saliva
  • Nasal/Throat Swabs
  • Other Sample Types

Technologies Covered:

  • Lateral Flow Assays
  • Immunoassays
  • Molecular Diagnostics
  • Microfluidics
  • Biosensors
  • Other Technologies

Applications Covered:

  • Diabetes Testing
  • Cardiovascular Diseases
  • Oncology Testing
  • Pregnancy & Fertility Testing
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Point-of-Care Diagnostic Devices Market, By Product Type

  • 5.1 Glucose Monitoring Devices
  • 5.2 Infectious Disease Testing Devices
  • 5.3 Cardiac Marker Testing Devices
  • 5.4 Blood Gas & Electrolyte Analyzers
  • 5.5 Other Product Types

6 Global Point-of-Care Diagnostic Devices Market, By Sample Type

  • 6.1 Blood
  • 6.2 Urine
  • 6.3 Saliva
  • 6.4 Nasal/Throat Swabs
  • 6.5 Other Sample Types

7 Global Point-of-Care Diagnostic Devices Market, By Technology

  • 7.1 Lateral Flow Assays
  • 7.2 Immunoassays
  • 7.3 Molecular Diagnostics
  • 7.4 Microfluidics
  • 7.5 Biosensors
  • 7.6 Other Technologies

8 Global Point-of-Care Diagnostic Devices Market, By Application

  • 8.1 Diabetes Testing
  • 8.2 Cardiovascular Diseases
  • 8.3 Oncology Testing
  • 8.4 Pregnancy & Fertility Testing
  • 8.5 Other Applications

9 Global Point-of-Care Diagnostic Devices Market, By End User

  • 9.1 Hospitals
  • 9.2 Clinics
  • 9.3 Diagnostic Centers
  • 9.4 Home Care Settings
  • 9.5 Other End Users

10 Global Point-of-Care Diagnostic Devices Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Abbott Laboratories
  • 13.2 Roche Diagnostics
  • 13.3 Siemens Healthineers
  • 13.4 Danaher Corporation
  • 13.5 Becton Dickinson and Company
  • 13.6 Bio-Rad Laboratories
  • 13.7 QuidelOrtho Corporation
  • 13.8 PerkinElmer Inc.
  • 13.9 Sekisui Diagnostics
  • 13.10 Trinity Biotech
  • 13.11 Arkray Inc.
  • 13.12 SD Biosensor Inc.
  • 13.13 Werfen
  • 13.14 Hologic Inc.
  • 13.15 Fujifilm Holdings Corporation

List of Tables

  • Table 1 Global Point-of-Care Diagnostic Devices Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Point-of-Care Diagnostic Devices Market, By Product Type (2023-2034) ($MN)
  • Table 3 Global Point-of-Care Diagnostic Devices Market, By Glucose Monitoring Devices (2023-2034) ($MN)
  • Table 4 Global Point-of-Care Diagnostic Devices Market, By Infectious Disease Testing Devices (2023-2034) ($MN)
  • Table 5 Global Point-of-Care Diagnostic Devices Market, By Cardiac Marker Testing Devices (2023-2034) ($MN)
  • Table 6 Global Point-of-Care Diagnostic Devices Market, By Blood Gas & Electrolyte Analyzers (2023-2034) ($MN)
  • Table 7 Global Point-of-Care Diagnostic Devices Market, By Other Product Types (2023-2034) ($MN)
  • Table 8 Global Point-of-Care Diagnostic Devices Market, By Sample Type (2023-2034) ($MN)
  • Table 9 Global Point-of-Care Diagnostic Devices Market, By Blood (2023-2034) ($MN)
  • Table 10 Global Point-of-Care Diagnostic Devices Market, By Urine (2023-2034) ($MN)
  • Table 11 Global Point-of-Care Diagnostic Devices Market, By Saliva (2023-2034) ($MN)
  • Table 12 Global Point-of-Care Diagnostic Devices Market, By Nasal/Throat Swabs (2023-2034) ($MN)
  • Table 13 Global Point-of-Care Diagnostic Devices Market, By Other Sample Types (2023-2034) ($MN)
  • Table 14 Global Point-of-Care Diagnostic Devices Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Point-of-Care Diagnostic Devices Market, By Lateral Flow Assays (2023-2034) ($MN)
  • Table 16 Global Point-of-Care Diagnostic Devices Market, By Immunoassays (2023-2034) ($MN)
  • Table 17 Global Point-of-Care Diagnostic Devices Market, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 18 Global Point-of-Care Diagnostic Devices Market, By Microfluidics (2023-2034) ($MN)
  • Table 19 Global Point-of-Care Diagnostic Devices Market, By Biosensors (2023-2034) ($MN)
  • Table 20 Global Point-of-Care Diagnostic Devices Market, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Point-of-Care Diagnostic Devices Market, By Application (2023-2034) ($MN)
  • Table 22 Global Point-of-Care Diagnostic Devices Market, By Diabetes Testing (2023-2034) ($MN)
  • Table 23 Global Point-of-Care Diagnostic Devices Market, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 24 Global Point-of-Care Diagnostic Devices Market, By Oncology Testing (2023-2034) ($MN)
  • Table 25 Global Point-of-Care Diagnostic Devices Market, By Pregnancy & Fertility Testing (2023-2034) ($MN)
  • Table 26 Global Point-of-Care Diagnostic Devices Market, By Other Applications (2023-2034) ($MN)
  • Table 27 Global Point-of-Care Diagnostic Devices Market, By End User (2023-2034) ($MN)
  • Table 28 Global Point-of-Care Diagnostic Devices Market, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Point-of-Care Diagnostic Devices Market, By Clinics (2023-2034) ($MN)
  • Table 30 Global Point-of-Care Diagnostic Devices Market, By Diagnostic Centers (2023-2034) ($MN)
  • Table 31 Global Point-of-Care Diagnostic Devices Market, By Home Care Settings (2023-2034) ($MN)
  • Table 32 Global Point-of-Care Diagnostic Devices Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.